Patents by Inventor Sougato Boral

Sougato Boral has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Indole-1-Carboxamides as Kinase Inhibitors
    Publication number: 20160096828
    Abstract: This invention is directed to a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, and X are as defined herein. The compounds of Formula I are useful as receptor tyrosine kinase (RTK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders and metabolic diseases.
    Type: Application
    Filed: October 7, 2014
    Publication date: April 7, 2016
    Inventors: Sougato Boral, Thomas C. Malone, Shimiao Wang
  • Substituted dialkyl(oxido)-lambda4-sulfanylidene nicotinamide derivatives as kinase inhibitors
    Patent number: 9266869
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Grant
    Filed: December 10, 2014
    Date of Patent: February 23, 2016
    Assignee: Allergan, Inc.
    Inventors: Sougato Boral, Shimiao Wang, Thomas Malone, Julie Wurster, Jie Shen, Michael Robinson
  • Kinase inhibitors
    Patent number: 9233968
    Abstract: Described herein are compounds which in some embodiments are capable of modulating, regulating, and/or inhibiting tyrosine kinase signal transduction, as well as methods and compositions related to the compounds.
    Type: Grant
    Filed: October 27, 2014
    Date of Patent: January 12, 2016
    Assignee: Allergan, Inc.
    Inventors: Sougato Boral, Shimiao Wang, Thomas C. Malone
  • SUBSTITUTED DIALKYL(OXIDO)-LAMBDA4-SULFANYLIDENE NICOTINAMIDE DERIVATIVES AS KINASE INHIBITORS
    Publication number: 20150166521
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Application
    Filed: December 10, 2014
    Publication date: June 18, 2015
    Inventors: Sougato Boral, Shimiao Wang, Thomas Malone, Julie Wurster, Jie Shen, Michael Robinson
  • SUBSTITUTED NICOTINAMIDE DERIVATIVES AS KINASE INHIBITORS
    Publication number: 20150166518
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Application
    Filed: December 10, 2014
    Publication date: June 18, 2015
    Inventors: Sougato Boral, Shimiao Wang, Thomas Malone, Julie Wurster, Jie Shen, Michael Robinson
  • 3-phenyl-5-ureidoisothiazole-4-carboximide and 3-amino-5-phenylisothiazole derivatives as kinase inhibitors
    Patent number: 8969583
    Abstract: This invention is directed to a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R, R1, R2, R3, n, X1, X2, L1, and L2 are as defined herein. The compounds of Formula I are useful as receptor tyrosine kinase (RTK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders and metabolic diseases.
    Type: Grant
    Filed: December 27, 2012
    Date of Patent: March 3, 2015
    Assignee: Allergan, Inc.
    Inventors: Thomas C. Malone, C. Eugene Hull, Sougato Boral, Julie A. Wurster, Michael R. Robinson, Jeffrey L. Edelman
  • Sulfoximines as kinase inhibitors
    Patent number: 8558002
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Grant
    Filed: October 20, 2011
    Date of Patent: October 15, 2013
    Assignee: Allergan, Inc.
    Inventors: Sougato Boral, Shimiao Wang, Julie A. Wurster
  • KINASE INHIBITORS
    Publication number: 20130267497
    Abstract: The present invention relates to drug delivery systems comprising ocular implant, which include organic molecules, capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation, in combination with a polymer, which polymer serves to control, modify, modulate and/or slow the release of the therapeutic component into the environment of the eye in which said composite is placed.
    Type: Application
    Filed: June 3, 2013
    Publication date: October 10, 2013
    Inventors: Lon T. Spada, Jane-Gou Shiah, Patrick M. Hughes, Thomas C. Malone, Gerald W. Devries, Jeffrey L. Edelman, Julie A. Wurster, Xialing Guo, Sougato Boral
  • Kinase inhibitors
    Patent number: 8455656
    Abstract: The present invention relates to drug delivery systems comprising ocular implant, which include organic molecules, capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation, in combination with a polymer, which polymer serves to control, modify, modulate and/or slow the release of the therapeutic component into the environment of the eye in which said composite is placed.
    Type: Grant
    Filed: February 26, 2009
    Date of Patent: June 4, 2013
    Assignee: Allergan, Inc.
    Inventors: Lon T. Spada, Jane Guo Shiah, Patrick Hughes, Thomas C. Malone, Gerald W. Devries, Jeffrey L. Edelman, Julie A. Wurster, Xialing Guo, Sougato Boral
  • Heteroaryl dihydroindolones as kinase inhibitors
    Patent number: 8455535
    Abstract: The present invention provides a compound represented by the formula: wherein ring systems A and B, and the variables R1, b, R6, Y, Z, X, R and a are defined in the specification. The compounds of the present invention may be used in a method for treating diseases related to unregulated tyrosine kinase signal transduction, such as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders, and metabolic diseases.
    Type: Grant
    Filed: June 1, 2011
    Date of Patent: June 4, 2013
    Assignee: Allergan, Inc.
    Inventors: Sougato Boral, Xialing Guo, Shimiao Wang, Julie A. Wurster, Thomas C. Malone
  • Kinase inhibitors
    Publication number: 20120238558
    Abstract: The present invention relates to drug delivery systems comprising ocular implant, which include organic molecules, capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation, in combination with a polymer, which polymer serves to control, modify, modulate and/or slow the release of the therapeutic component into the environment of the eye in which said composite is placed.
    Type: Application
    Filed: February 26, 2009
    Publication date: September 20, 2012
    Inventors: Lon T. Spada, Jane Guo Shiah, Patrick Hughes, Thomas C. Malone, Gerald W. DeVries, Jeffrey L. Edelman, Julie A. Wurster, Xialing Guo, Sougato Boral
  • SULFOXIMINES AS KINASE INHIBITORS
    Publication number: 20120196902
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Application
    Filed: October 20, 2011
    Publication date: August 2, 2012
    Inventors: Sougato Boral, Shimiao Wang, JULIE A. WURSTER
  • Heteroaryl Dihydroindolones as Kinase Inhibitors
    Publication number: 20110257238
    Abstract: The present invention provides a compound represented by the formula: wherein the variables R1, b, R6, Y, Z, X, R and a are defined in the specification. Said compound may be used in a method for treating diseases related to unregulated tyrosine kinase signal transduction, wherein said disease is selected from the group consisting of cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders, and metabolic diseases.
    Type: Application
    Filed: June 1, 2011
    Publication date: October 20, 2011
    Applicant: ALLERGAN, INC.
    Inventors: Sougato Boral, Xialing Guo, Shimiao Wang, Julie A. Wurster, Thomas C. Malone
  • Heteroaryl dihydroindolones as kinase inhibitors
    Patent number: 7977351
    Abstract: The present invention provides a compound represented by the formula: wherein the variables R1, b, R6, Y, Z, X, R and a are defined in the specification. Said compound may be used in a method for treating diseases related to unregulated tyrosine kinase signal transduction, wherein said disease is selected from the group consisting of cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders, and metabolic diseases.
    Type: Grant
    Filed: March 16, 2007
    Date of Patent: July 12, 2011
    Assignee: Allergan, Inc.
    Inventors: Sougato Boral, Xialing Guo, Shimiao Wang, Julie A. Wurster, Thomas C. Malone
  • Sulfoximines as kinase inhibitors
    Patent number: 7915443
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Grant
    Filed: November 16, 2007
    Date of Patent: March 29, 2011
    Assignee: Allergan, Inc.
    Inventors: Julie A. Wurster, Clarence Eugene Hull, III, Richard C. Yee, Sougato Boral, Shimiao Wang, Thomas C. Malone
  • Kinase inhibitors
    Publication number: 20090286773
    Abstract: The present invention relates to drug delivery systems comprising ocular implant, which include organic molecules, capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation, in combination with a polymer, which polymer serves to control, modify, modulate and/or slow the release of the therapeutic component into the environment of the eye in which said composite is placed.
    Type: Application
    Filed: February 26, 2009
    Publication date: November 19, 2009
    Inventors: Lon T. Spada, Jane Guo Shiah, Patrick Hughes, Thomas C. Malone, Gerald W. DeVries, Jeffrey L. Edelman, Julie A. Wurster, Xialing Guo, Sougato Boral
  • SULFOXIMINES AS KINASE INHIBITORS
    Publication number: 20090099181
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Application
    Filed: November 16, 2007
    Publication date: April 16, 2009
    Inventors: Julie A. Wurster, Clarence Eugene Hull, III, Richard C. Yee, Sougato Boral, Shimiao Wang, Thomas C. Malone
  • HETEROARYL DIHYDROINDOLONES AS KINASE INHIBITORS
    Publication number: 20080045526
    Abstract: The present invention provides a compound represented by the formula: wherein the variables R1, b, R6, Y, Z, X, R and a are defined in the specification. Said compound may be used in a method for treating diseases related to unregulated tyrosine kinase signal transduction, wherein said disease is selected from the group consisting of cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders, and metabolic diseases.
    Type: Application
    Filed: March 16, 2007
    Publication date: February 21, 2008
    Inventors: Sougato Boral, Xialing Guo, Shimiao Wang, Julie A. Wurster, Thomas C. Malone